Intercept Pharmaceuticals, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
SAVACassava Sciences, Inc. -5.17%45.850.0%$286.15m
HZNPHorizon Therapeutics Plc -3.75%99.845.4%$179.80m
VRXValeant Pharmaceuticals International, Inc. 1.11%23.7214.1%$139.57m
CTLTCatalent, Inc. -4.16%122.342.0%$139.08m
ICLRICON plc -0.09%272.812.8%$113.67m
JAZZJazz Pharmaceuticals Plc -1.99%120.262.1%$75.13m
UTHRUnited Therapeutics Corp. -1.74%185.9913.9%$72.82m
PRGOPerrigo Co. Plc -0.17%35.776.9%$61.33m
BHCBausch Health Cos., Inc. 1.11%23.720.0%$61.23m
ARGXargenx SE -3.80%283.700.0%$57.55m
CPIXCumberland Pharmaceuticals, Inc. 8.77%4.590.6%$53.98m
ENDPEndo International Plc -5.49%4.998.5%$43.65m
IRWDIronwood Pharmaceuticals, Inc. -1.17%10.989.5%$25.02m
PCRXPacira Biosciences, Inc. -2.27%52.539.8%$24.33m
AXSMAxsome Therapeutics, Inc. -3.33%32.241.8%$22.43m

Company Profile

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.